Your browser doesn't support javascript.
loading
Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Yardley, Denise A; Dickson, Natalie; Drosick, David; Earwood, Chris; Inhorn, Roger; Murphy, Patrick; Hainsworth, John D.
Afiliação
  • Yardley DA; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN. Electronic address: dyardley@tnonc.com.
  • Dickson N; Tennessee Oncology, PLLC, Nashville, TN.
  • Drosick D; Oncology Hematology Care, Cincinnati, OH.
  • Earwood C; Sarah Cannon Research Institute, Nashville, TN.
  • Inhorn R; Mercy Hospital, Portland, ME.
  • Murphy P; Tennessee Oncology, PLLC, Nashville, TN.
  • Hainsworth JD; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.
Clin Breast Cancer ; 16(3): 180-7, 2016 06.
Article em En | MEDLINE | ID: mdl-26943991
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Niacinamida / Epotilonas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Niacinamida / Epotilonas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article